ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ENGN vs TNYA // ENTERPRISE SCALE & MARKET CAP

enGene Therapeutics Inc. (NASDAQ) VS. Tenaya Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ENGN 2 — TNYA 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ENGN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENGN VS. TNYA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ENGN TNYA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 TNYA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.0 27.5 +9.48 ENGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $102.5M $90.8M $11.7M ENGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ENGN REV TNYA REV ENGN GROSS % TNYA GROSS % ENGN FCF TNYA FCF
FY 2025 $0 $0 — — -$100.7M -$68.9M
FY 2024 $0 $0 — — -$49.2M -$91.5M
FY 2023 $0 $0 — — -$24.7M -$102.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENGN // BETA —
TNYA // BETA —